Clinical trials: Second-Line
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
- Trial name
- NCT05564403
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 207 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study…
- Conditions
- Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
- Trial name
- NCT06446154
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Evaluating the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressive gastric cancer
- Trial name
- NCT06697366
- Testing
- Irinotecan liposome injection Ⅱ, Sintilimab
- Volunteers
- 27 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer (NSCLC), Lung Cancer
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
- Trial name
- NCT00227019
- Testing
- Bevacizumab, Pemetrexed, Vitamin B12
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Heather Wakelee
Colorectal Cancer
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
- Trial name
- NCT02718430
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Vaximm GmbH
Lung Cancer, Non-small Cell Lung Cancer
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to…
- Trial name
- NCT00721981
- Where
- 8 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
The purpose of this study is to see whether an altered schedule of giving erlotinib in combination with gemcitabine will be safe and might improve the results of the treatment for advanced cancer of the pancreas.
- Trial name
- NCT02154737
- Testing
- Gemcitabine, Erlotinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tony Reid, M.D., Ph.D.
Helicobacter Pylori Infection, Eradication Treatments
Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia
Study is prospective randomised multicentric. The primary objective of the study is to compare the efficacy of two first-line therapy regimens and two second-line therapy regimens (ie, after failure of first-line treatment) in…
- Trial name
- NCT04359966
- Testing
- Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,, Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg, Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg
- Where
- 3 sites in Slovenia
- Volunteers
- 560 people
- Sponsor
- Slovenian Society for Gastroenterology and Hepatology
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Gastric Adenocarcinoma
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
Phase II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET overexpression as a second-line treatment.
- Trial name
- NCT02447380
- Testing
- AZD6094, Docetaxel
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Samsung Medical Center
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with…
- Trial name
- NCT00454779
- Testing
- Cisplatin, Panitumumab, Docetaxel
- Where
- 114 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Amgen
Colorectal Cancer
TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
The purpose of this study: To explore the comparative effectiveness of BIBF 1120 in terms of : Progression-free survival (PFS), objective response, overall survival Evaluate and compare safety
- Trial name
- AIO-KRK-0111 (NCT01362361)
- Testing
- mFOLFOX6 + BIBF 1120
- Where
- 12 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or…
- Trial name
- NCT07362186
- Testing
- LM-108 in combination with Toripalimab, Paclitaxel injection intravenous infusion
- Where
- China
- Volunteers
- 400 people
- Sponsor
- LaNova Medicines Limited
Advanced Renal Cell Carcinoma (aRCC)
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination…
- Trial name
- CARINA (NCT04957160)
- Where
- 9 sites in United Kingdom
- Volunteers
- 281 people
- Sponsor
- Ipsen
Metastatic Breast Cancer
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01451580
- Testing
- Lipo-Dox
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- TTY Biopharm
Advanced Breast Cancer
Second Line Breast Cancer Trial
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
- Trial name
- NCT00635713
- Testing
- Fulvestrant, Anastrozole
- Volunteers
- 588 people
- Sponsor
- AstraZeneca
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid…
- Trial name
- NCT02154490
- Testing
- Docetaxel, Durvalumab, Erlotinib Hydrochloride
- Where
- 1,004 sites in United States, Canada
- Volunteers
- 1,864 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer
This is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally…
- Trial name
- NCT07773363
- Testing
- Retlirafusp Alfa, Apatinib, Fluoropyrimidine-Based Chemotherapy
- Volunteers
- 37 people
- Sponsor
- Tang-Du Hospital
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Parkinson Disease
Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease
Since our previous study has shown that some personality dimensions were associated with Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's disease (PD), the investigators aim to evaluate the…
- Trial name
- PERSO-PERF (NCT06080399)
- Testing
- Continuous subcutaneous apomorphine infusion (CSAI)
- Where
- 10 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Toulouse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.